A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs CLR 457 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2016 The trial was completed in France (end date: 2015-11-12).
- 14 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.